secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0001564590-22-006498
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi's Haduvio meets Phase 2 CANAL primary endpoint; 52% placebo-adjusted cough reduction in IPF patients
--------------------------------------------------------------------------------

- Interim analysis (N=26) showed 52% placebo-adjusted reduction in daytime cough frequency (p<0.0001); 100% probability of success.
- Company stops further recruitment into CANAL trial based on strong and consistent interim data.
- Haduvio well tolerated; no new safety signals; one unrelated SAE reported.
- Full CANAL trial data expected early Q3 2022, with approximately 40 total subjects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022006498/0001564590-22-006498-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022006498/trvi-8k_20220224.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-006498

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer